Theraclone licenses HIV mAbs to Gilead
Theraclone Sciences Inc. (Seattle, Wash.) granted Gilead Sciences Inc. (NASDAQ:GILD) exclusive rights to develop and commercialize products incorporating Theraclone's preclinical broadly neutralizing HIV antibodies (bNAbs) for therapeutic applications. Theraclone received an undisclosed upfront payment and is eligible to receive undisclosed development and commercialization milestones. The deal includes bNAbs targeting a glycan-dependent epitope on the pre-fusion conformation of HIV gp41 on cleaved HIV env trimers as well as bNAbs targeting a variety of epitopes on HIV gp120, including PG9 and PG16.
The Scripps Research Institute and the International AIDS Vaccine Initiative (IAVI) discovered the bNAbs using Theraclone's I-STAR antibody discovery technology. IAVI has rights to develop HIV vaccines based on the bNAbs. Gilead declined to comment on the deal. ...